Analysts Issue Forecasts for Tyra Biosciences, Inc.'s Q1 2025 Earnings (NASDAQ:TYRA)

Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of Tyra Biosciences in a research report issued on Thursday, May 9th. Wedbush analyst R. Driscoll forecasts that the company will earn ($0.41) per share for the quarter. Wedbush currently has a "Outperform" rating and a $28.00 price objective on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($1.89) per share. Wedbush also issued estimates for Tyra Biosciences' Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.42) EPS and Q4 2025 earnings at ($0.44) EPS.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 19th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.05).

TYRA has been the topic of a number of other research reports. HC Wainwright reiterated a "buy" rating and issued a $23.00 target price on shares of Tyra Biosciences in a report on Friday. Oppenheimer reiterated an "outperform" rating and issued a $28.00 target price (up previously from $25.00) on shares of Tyra Biosciences in a report on Monday.

Tyra Biosciences Stock Performance

Tyra Biosciences stock traded up $1.15 during midday trading on Monday, reaching $18.50. The stock had a trading volume of 86,080 shares, compared to its average volume of 129,314. Tyra Biosciences has a twelve month low of $10.38 and a twelve month high of $20.67. The stock has a market capitalization of $971.99 million, a PE ratio of -10.92 and a beta of 1.08. The stock's 50-day simple moving average is $17.04 and its 200 day simple moving average is $15.13.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, COO Daniel Bensen sold 1,733 shares of the firm's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $20.09, for a total value of $34,815.97. Following the transaction, the chief operating officer now directly owns 431,951 shares of the company's stock, valued at $8,677,895.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 4,728 shares of company stock valued at $94,716 over the last three months. 15.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Simplex Trading LLC increased its position in shares of Tyra Biosciences by 198.1% during the third quarter. Simplex Trading LLC now owns 2,009 shares of the company's stock worth $27,000 after acquiring an additional 1,335 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Tyra Biosciences by 1,244.2% during the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company's stock worth $29,000 after acquiring an additional 1,916 shares during the last quarter. AJOVista LLC purchased a new stake in shares of Tyra Biosciences during the fourth quarter worth about $59,000. Exchange Traded Concepts LLC increased its position in shares of Tyra Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company's stock worth $132,000 after acquiring an additional 2,417 shares during the last quarter. Finally, Corton Capital Inc. purchased a new stake in shares of Tyra Biosciences during the third quarter worth about $152,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.